Topamax 100 mg film-coated tablets
Authorisation PPA0465/196/003 · PCO Manufacturing Ltd.
- Licence holder
- PCO Manufacturing Ltd. (all products →)
- Active substance
- Topiramate
- Clinical trials
- 4 clinical trials →
- Dosage form
- Film-coated tablet
- Route of administration
- Oral use
- ATC codes
- N03AX, N03AX11
- First authorised
- 16/03/2007
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Parallel importation notified in accordance with Article 76(3) of Directive 2001/83/EC
Topiramate: supply and approvals
23 authorised products on the HPRA list contain Topiramate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- Topamax: Shortage ongoing, first published 29 Jun 2026
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Parallel import (PPA). A parallel product authorisation: the HPRA allows this product to be imported from another EU or EEA country and sold in Ireland. It has been authorised for 19 years (since 16 March 2007). The HPRA list does not say whether it is on sale.
Other medicines with Topiramate in Ireland
22 other products on the HPRA list contain Topiramate, from 6 licence holders; 6 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| TOPAMAX 100 mg Film-coated Tablets | Janssen Sciences Ireland Unlimited Company | National authorisation (PA) | Marketed |
| TOPAMAX 200mg Film-coated Tablets | Janssen Sciences Ireland Unlimited Company | National authorisation (PA) | Marketed |
| TOPAMAX 25mg Film-coated Tablets | Janssen Sciences Ireland Unlimited Company | National authorisation (PA) | Marketed |
| TOPAMAX 50mg Film-coated Tablets | Janssen Sciences Ireland Unlimited Company | National authorisation (PA) | Marketed |
| Topamax Sprinkle 15 mg Hard Capsules | Janssen Sciences Ireland Unlimited Company | National authorisation (PA) | Marketed |
| Topamax Sprinkle 25 mg Hard Capsules | Janssen Sciences Ireland Unlimited Company | National authorisation (PA) | Marketed |
| Qsiva 11.25 mg/69 mg hard modified-release capsules | Vivus B.V. | National authorisation (PA) | Not marketed |
| Qsiva 15 mg/92 mg hard modified-release capsules | Vivus B.V. | National authorisation (PA) | Not marketed |
| Qsiva 3.75 mg/23 mg hard modified-release capsules | Vivus B.V. | National authorisation (PA) | Not marketed |
| Qsiva 7.5 mg/46 mg hard modified-release capsules | Vivus B.V. | National authorisation (PA) | Not marketed |
| TOPAMAX 100 mg Film-coated Tablets | Originalis B.V. | Parallel import (PPA) | Not stated |
| TOPAMAX 100 mg film-coated tablets | IMED Healthcare Ltd., | Parallel import (PPA) | Not stated |
Other substances in ATC group N03AX
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 11 other active substances share the group N03AX with this product:
Pregabalin (34) · Levetiracetam (31) · Lamotrigine (26) · Lacosamide (12) · Perampanel (7) · Cenobamate (5) · Stiripentol (4) · Zonisamide (3) · CANNABIDIOL (1) · Fenfluramine hydrochloride (1) · Ganaxolone (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
PCO Manufacturing Ltd. holds 287 products on the HPRA list, with 163 different active substances; 1 of the products is marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.